Cargando…
CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and en...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499619/ https://www.ncbi.nlm.nih.gov/pubmed/37719875 http://dx.doi.org/10.3389/fnagi.2023.1214932 |
_version_ | 1785105748889436160 |
---|---|
author | Dong, Ruocheng Lu, Qiongshi Kang, Hyunseung Suridjan, Ivonne Kollmorgen, Gwendlyn Wild, Norbert Deming, Yuetiva Van Hulle, Carol A. Anderson, Rozalyn M. Zetterberg, Henrik Blennow, Kaj Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Engelman, Corinne D. |
author_facet | Dong, Ruocheng Lu, Qiongshi Kang, Hyunseung Suridjan, Ivonne Kollmorgen, Gwendlyn Wild, Norbert Deming, Yuetiva Van Hulle, Carol A. Anderson, Rozalyn M. Zetterberg, Henrik Blennow, Kaj Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Engelman, Corinne D. |
author_sort | Dong, Ruocheng |
collection | PubMed |
description | INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and enhance our knowledge of the disease. METHODS: The relative abundance of untargeted metabolites was assessed in 161 individuals from the Wisconsin Registry for Alzheimer’s Prevention. A metabolome-wide association study (MWAS) was conducted between 269 CSF metabolites and protein biomarkers reflecting brain amyloidosis, tau pathology, neuronal and synaptic degeneration, and astrocyte or microglial activation and neuroinflammation. Linear mixed-effects regression analyses were performed with random intercepts for sample relatedness and repeated measurements and fixed effects for age, sex, and years of education. The metabolome-wide significance was determined by a false discovery rate threshold of 0.05. The significant metabolites were replicated in 154 independent individuals from then Wisconsin Alzheimer’s Disease Research Center. Mendelian randomization was performed using genome-wide significant single nucleotide polymorphisms from a CSF metabolites genome-wide association study. RESULTS: Metabolome-wide association study results showed several significantly associated metabolites for all the biomarkers except Aβ42/40 and IL-6. Genetic variants associated with metabolites and Mendelian randomization analysis provided evidence for a causal association of metabolites for soluble triggering receptor expressed on myeloid cells 2 (sTREM2), amyloid β (Aβ40), α-synuclein, total tau, phosphorylated tau, and neurogranin, for example, palmitoyl sphingomyelin (d18:1/16:0) for sTREM2, and erythritol for Aβ40 and α-synuclein. DISCUSSION: This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal. |
format | Online Article Text |
id | pubmed-10499619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104996192023-09-15 CSF metabolites associated with biomarkers of Alzheimer’s disease pathology Dong, Ruocheng Lu, Qiongshi Kang, Hyunseung Suridjan, Ivonne Kollmorgen, Gwendlyn Wild, Norbert Deming, Yuetiva Van Hulle, Carol A. Anderson, Rozalyn M. Zetterberg, Henrik Blennow, Kaj Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Engelman, Corinne D. Front Aging Neurosci Neuroscience INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and enhance our knowledge of the disease. METHODS: The relative abundance of untargeted metabolites was assessed in 161 individuals from the Wisconsin Registry for Alzheimer’s Prevention. A metabolome-wide association study (MWAS) was conducted between 269 CSF metabolites and protein biomarkers reflecting brain amyloidosis, tau pathology, neuronal and synaptic degeneration, and astrocyte or microglial activation and neuroinflammation. Linear mixed-effects regression analyses were performed with random intercepts for sample relatedness and repeated measurements and fixed effects for age, sex, and years of education. The metabolome-wide significance was determined by a false discovery rate threshold of 0.05. The significant metabolites were replicated in 154 independent individuals from then Wisconsin Alzheimer’s Disease Research Center. Mendelian randomization was performed using genome-wide significant single nucleotide polymorphisms from a CSF metabolites genome-wide association study. RESULTS: Metabolome-wide association study results showed several significantly associated metabolites for all the biomarkers except Aβ42/40 and IL-6. Genetic variants associated with metabolites and Mendelian randomization analysis provided evidence for a causal association of metabolites for soluble triggering receptor expressed on myeloid cells 2 (sTREM2), amyloid β (Aβ40), α-synuclein, total tau, phosphorylated tau, and neurogranin, for example, palmitoyl sphingomyelin (d18:1/16:0) for sTREM2, and erythritol for Aβ40 and α-synuclein. DISCUSSION: This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10499619/ /pubmed/37719875 http://dx.doi.org/10.3389/fnagi.2023.1214932 Text en Copyright © 2023 Dong, Lu, Kang, Suridjan, Kollmorgen, Wild, Deming, Van Hulle, Anderson, Zetterberg, Blennow, Carlsson, Asthana, Johnson and Engelman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Dong, Ruocheng Lu, Qiongshi Kang, Hyunseung Suridjan, Ivonne Kollmorgen, Gwendlyn Wild, Norbert Deming, Yuetiva Van Hulle, Carol A. Anderson, Rozalyn M. Zetterberg, Henrik Blennow, Kaj Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Engelman, Corinne D. CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title_full | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title_fullStr | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title_full_unstemmed | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title_short | CSF metabolites associated with biomarkers of Alzheimer’s disease pathology |
title_sort | csf metabolites associated with biomarkers of alzheimer’s disease pathology |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499619/ https://www.ncbi.nlm.nih.gov/pubmed/37719875 http://dx.doi.org/10.3389/fnagi.2023.1214932 |
work_keys_str_mv | AT dongruocheng csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT luqiongshi csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT kanghyunseung csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT suridjanivonne csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT kollmorgengwendlyn csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT wildnorbert csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT demingyuetiva csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT vanhullecarola csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT andersonrozalynm csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT zetterberghenrik csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT blennowkaj csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT carlssoncynthiam csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT asthanasanjay csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT johnsonsterlingc csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology AT engelmancorinned csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology |